SCHEDULE 13G/A: BlackRock Amends Stake in Caribou Biosciences, Discloses 6.8% Passive Ownership

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 6.8% passive beneficial ownership stake in Caribou Biosciences, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 2 to Schedule 13G regarding its ownership in Caribou Biosciences, Inc.
• As of March 31, 2025, BlackRock, Inc. beneficially owned an aggregate of 6,281,683 shares of Caribou Biosciences, Inc. Common Stock.
• This represents 6.8% of the total outstanding Common Stock of Caribou Biosciences, Inc.
• BlackRock holds sole voting power over 6,176,047 shares and sole dispositive power over 6,281,683 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• The filing lists several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, as entities through which the securities are reported.

Sentiment

Score: 6

Explanation: The document is a neutral, factual disclosure of beneficial ownership. It indicates a stable, passive institutional investment, which is generally positive for a company, but contains no new operational or financial news to significantly alter sentiment.

Positives

• BlackRock's continued significant passive investment (6.8%) in Caribou Biosciences, Inc. indicates a long-term, non-activist interest in the company.
• The filing confirms the investment is for ordinary course of business, suggesting a stable, institutional holding.

Future Outlook

The document is a routine ownership disclosure and does not provide any forward-looking statements or guidance regarding Caribou Biosciences, Inc.'s future performance or BlackRock's investment strategy beyond the passive nature of the holding.

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Signed by Spencer Fleming, Managing Director of BlackRock, Inc.)

Industry Context

This filing is a standard disclosure by a large institutional investor, BlackRock, Inc., indicating its passive ownership stake in Caribou Biosciences, Inc., a biotechnology company. Such filings are common and reflect ongoing portfolio management by major asset managers. It does not provide specific insights into the biotechnology industry trends but rather confirms BlackRock's continued investment in the sector through Caribou Biosciences.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming a passive investment approach.
• Management: Awareness of a large, stable institutional investor on the shareholder register.

Next Steps

• BlackRock, Inc. will continue to file amendments to Schedule 13G if there are significant changes (e.g., 1% or more) in its beneficial ownership of Caribou Biosciences, Inc. or if its investment intent changes from passive.

Key Dates

Recommendation

Keywords

BlackRock, Caribou Biosciences, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing